The accumulation of relevant information cumulatively revealed that, in vivo, miR-138 preferentially modulates the immune system, especially interacting with PD-1 and CTLA-4 to inhibit tumor-infiltrating Tregs and later alleviating the damage by immunological disorder cells in the tumor microenvironment (22). Here, PDCD1 is linked to neoplasm.